摘要
目的探讨来氟米特联合科素亚治疗IgA肾病的疗效。方法 40例IgA肾病患者按照就诊时间顺序分为单纯科素亚治疗组(科素亚组)及来氟米特联合科素亚治疗组(联合组)。分析两组治疗后1、3、6个月24 h尿蛋白定量、血浆白蛋白、肾功能变化及不良反应。结果治疗3个月时,与科素亚组[(1.28±0.49)g/d]比较,联合组[(0.92±0.53)g/d]能明显降低24 h尿蛋白定量,两组治疗前后差异有统计学意义(P<0.05)。结论来氟米特联合科素亚治疗IgA肾病,较单纯应用科素亚能减少蛋白尿,延缓肾功能进展。
Objective To study the effects of combined leflunomide and cozaar therapy on IgA nephropathy.Methods Forty patients with IgA nephropathy diagnosed by renal biopsy were randomly divided into two groups： cozaar（100 mg/d） treated group and leflunomide（20mg/d） plus cozaar treated group.The changes in proteinuria and serum creatinine were observed.Results After 1 month treatment by the two methods,the level of proteinuria decreased significantly [（0.92±0.53） vs（1.28±0.99）]（P〈0.05）in all.After 3 and 6 months of treatment,the level of proteinuria in combined leflunomide and cozaar therapy group was lower than that in cozaar therapy group（P〈0.05）.Conclusions Combined leflunomide and cozaar therapy reduces 24 h urine proteinuria and protects renal function in patients with IgA nephropathy.
出处
《武警医学》
CAS
2012年第7期599-600,604,共3页
Medical Journal of the Chinese People's Armed Police Force
